



Please type a plus sign (+) inside this box → ☒

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known	
Application Number	10/812,776			
Filing Date	March 29, 2004			
First Named Inventor	David F. Muir			
Group Art Unit	3731			
Examiner Name				
Attorney Docket Number	UF-336XC3D1			

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
VA	U1	2003/0068815	A1	Stone et al.	04-10-2003	All
VA	U2	2001/0039459	A1	Stone	11-08-2001	All
VA	U3	2001/0034043	A1	Su et al.	10-25-2001	All
VA	U4	6,455,309	B2	Stone	09-24-2002	All
VA	U5	6,267,786	B1	Stone	07-31-2001	All
VA	U6	6,231,608	B1	Stone	05-15-2001	All
VA	U7	6,093,563		Bennett et al.	07-25-2000	All
VA	U8	6,054,569		Bennett et al.	04-25-2000	All
VA	U9	5,997,863		Zimmermann et al.	12-07-1999	All
VA	U10	5,916,557		Berlowitz-Tarrant et al.	06-29-1999	All
VA	U11	5,716,617		Khandke et al.	02-10-1998	All
VA	U12	5,292,509		Hageman	03-08-1994	All
VA	U13	5,231,580		Cheung et al.	07-27-1993	All
VA	U14	4,933,185		Wheatley et al.	06-12-1990	All
VA	U15	4,696,816		Brown	09-29-1987	All
VA	U16	10/218,316		Muir (patent application)	08-13-2002	All
VA	U17	10/218,315		Muir (patent application)	08-13-2002	All

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
VA	F1	WO	91/06573	A1	La Jolla Cancer Res. Foundation	05-16-1991	All	
VA	F2	WO	91/06303	A1	Case Western Reserve Univ.	05-16-1991	All	
VA	F3	WO	01/39795	A2	IBEX Tech., Inc.	06-07-2001	All	
VA	F4	WO	01/35977	A2	IBEX Tech., Inc.	05-25-2001	All	
VA	F5	EP	0 875 253	A2	Seikagaku Corp.	11-04-1998	All	
VA	F6	EP	0 613 949	A2	Maruha Corporation	09-07-1994	All	
VA	F7	EP	0 776 968	A1	Sumitomo Bakelite Co.	06-04-1997	All	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/812,776
				Filing Date	March 29, 2004
				First Named Inventor	David F. Muir
				Group Art Unit	3731
				Examiner Name	
				Attorney Docket Number	UF-336XC3D1
Sheet	2	of	7		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
VA	U18	6,200,564	B1	Lamont et al.	03-13-2001	All
VA	U19	6,214,978	B1	Truog et al.	04-10-2001	All
VA	U20	5,866,120		Karageozian et al.	02-02-1999	All
VA	U21	5,830,468		Bini	11-03-1998	All
	U22					
	U23					
	U24					
	U25					
	U26					
	U27					
	U28					
	U29					
	U30					
	U31					
	U32					
	U33					
	U34					

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
VA	F8	EP	0 576 294	A2	Seikagaku Kogyo Kabushiki Kaisha	12-29-1993	All	
VA	F9	DE	19530556		Minuth Will Prof Dr	09-05-1996	All	
VA	F10	DE	19530556 (English abstract)		Minuth Will Prof Dr	09-05-1996	All	
	F11							
	F12							
	F13							
	F14							

Examiner Signature		Date Considered	1-27-2006
--------------------	--	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

+

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete If Known		
			Application Number	10/812,776	
			Filing Date	March 29, 2004	
			First Named Inventor	David F. Muir	
			Group Art Unit	3731	
			Examiner Name		
Sheet	3	of	7	Attorney Docket Number	UF-336XC3D1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
VA	R1	AGIUS, E. and P. COCHARD "Comparison of Neurite Outgrowth Induced by Intact and Injured Sciatic Nerves: A Confocal and Functional Analysis" <i>The Journal of Neuroscience</i> , January 1, 1998, 18(1):328-338.		
VA	R2	BENNETT, G.S. <i>et al.</i> "Chondroitinase ABC delivered to the site of a spinal cord injury upregulates GAP-43 expression in dorsal root ganglion neurons" <i>Society for Neuroscience Abstracts</i> , 2000. 26(1-2):Abstract no. 324.3 from 30 th Annual Meeting of the Society of Neuroscience, presented November, 2000; mailed to subscribers September, 2000.		
VA	R3	BERTOLOTTI, A. <i>et al.</i> "Immunohistochemical Localization of Chondroitin Sulfate in Normal and Pathological Human Muscle" <i>J Neurol Sci</i> , 1986, 73:233-244.		
VA	R4	BRADBURY, E.J. <i>et al.</i> "Chondroitinase ABC promotes functional recovery after spinal cord injury" <i>Nature</i> , April 2002, 416(6881):636-640.		
VA	R5	BRADBURY, E.J. <i>et al.</i> "Chondroitinase ABC promotes functional recovery after spinal cord injury" <i>Nature</i> , 2002, 416:636-640. <i>duplicate</i>		
VA	R6	BRADBURY, E.J. <i>et al.</i> "Chondroitinase ABC Delivered to the Site of a Spinal Cord Injury Upregulates GAP-43 Expression in Dorsal Root Ganglion Neurons" <i>Soc. Neurosci Abstr</i> , November 2000, abstract presented at the 30 th Annual Meeting of the Society of Neuroscience.		
VA	R7	BRAUNEWELL, K-H. <i>et al.</i> "Functional Involvement of Sciatic Nerve-derived Versican- and Decorin-like Molecules and other Chondroitin Sulphate Proteoglycans in ECM-mediated Cell Adhesion and Neurite Outgrowth" <i>Euro. J. Neurosci.</i> , 1995, 7:805-814.		
VA	R8	BRAUNEWELL, K-H. <i>et al.</i> "Up-regulation of a Chondroitin Sulphate Eptiope during Regeneration of Mouse Sciatic Nerve: Evidence that the Immunoreactive Molecules are Related to the Chondroitin Sulphate Proteoglycans Decorin and Versican" <i>Eur J Neurosci</i> , 1995, 7:792-804.		
VA	R9	BROWN, M.C. <i>et al.</i> "Further Studies on Motor and Sensory Nerve Regeneration in Mice With Delayed Wallerian Degeneration" <i>Eur J Neurosci</i> , 1994, 6:420-428.		
VA	R10	DANIELSEN, N. <i>et al.</i> "Predegeneration enhances regeneration into acellular nerve grafts" <i>Brain Res</i> , 1995, 681:105-108.		
VA	R11	DANIELSEN, N. <i>et al.</i> "Pre-degenerated nerve grafts enhance regeneration by shortening the initial delay period" <i>Brain Res</i> , 1994, 666:250-254.		
VA	R12	EVANS, P.J. <i>et al.</i> "Regeneration Across Cold Preserved Peripheral Nerve Allografts" <i>Microsurgery</i> , 1999, 19:115-127.		
VA	R13	EVANS, P.J. <i>et al.</i> "The Peripheral Nerve Allograft: A Comprehensive Review of Regeneration and Neuroimmunology" <i>Prog Neurobiol</i> , 1994, 43:187-233.		

Examiner Signature	<i>V. Afonso</i>	Date Considered	1-27-2006
--------------------	------------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/812,776
				Filing Date	March 29, 2004
				First Named Inventor	David F. Muir
				Group Art Unit	3731
				Examiner Name	
Sheet	4	of	7	Attorney Docket Number	UF-336XC3D1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
VA	R14	EVANS, P.J. <i>et al.</i> "Cold Preserved Nerve Allografts: Changes in Basement Membrane, Viability, Immunogenicity, and Regeneration" <i>Muscle Nerve</i> , November 1998, 21:1507-1522.		
VA	R15	FAWCETT, J.W. and R.J. KEYNES "Peripheral Nerve Regeneration" <i>Annu Rev Neurosci</i> , 1990, 13:43-60.		
VA	R16	FERGUSON, T.A. and D. Muir "MMP-2 and MMP-9 Increase the Neurite-Promoting Potential of Schwann Cell Basal Laminae and Are Upregulated in Degenerated Nerve" <i>Mol Cell Neurosci</i> , 2000 16:157-167.		
VA	R17	FU, S.Y. and T. Gordon "The Cellular and Molecular Basis of Peripheral Nerve Regeneration" <i>Mol Neurobiol</i> , 1997, 14(1):67-116.		
VA	R18	GIANNINI, C. and P. DYCK "The Fate of Schwann Cell Basement Membranes in Permanently Transected Nerves" <i>J Neuropathol Exp Neurol</i> , 1990, 49(6):550-563.		
VA	R19	GORDON, L. <i>et al.</i> "Predegenerated nerve autografts as compared with fresh nerve autografts in freshly cut and precut motor nerve defects in the rat" <i>J Hand Surg [Am]</i> , January 1979, 4(1):42-47.		
VA	R20	GULATI, A.K. "Evaluation of acellular and cellular nerve grafts in repair of rat peripheral nerve" <i>J Neurosurg</i> , January 1988, 68:117-123.		
VA	R21	HASAN, N. <i>et al.</i> "The influence of predegenerated nerve grafts on axonal regeneration from prelesioned peripheral nerves" <i>J Anat</i> , 1996, 189:293-302.		
VA	R22	IDE, C. <i>et al.</i> "Schwann Cell Basal Lamina and Nerve Regeneration" <i>Brain Res</i> , 1983, 288:61-75.		
VA	R23	JONES, L.L. <i>et al.</i> "Neurotrophic factors, cellular bridges and gene therapy for spinal cord injury" <i>J. Physiology</i> , 2001, 533.1:83-89.		
VA	R24	KHERIF, S. <i>et al.</i> "Matrix metalloproteinases MMP-2 and MMP-9 in denervated muscle and injured nerve" <i>Neuropathol Appl Neurobiol</i> , 1998, 24:309-319.		
VA	R25	KREKOSKI, C.A. <i>et al.</i> "Metalloproteinase-Dependent Predegeneration <i>In Vitro</i> Enhances Axonal Regeneration within Acellular Peripheral Nerve Grafts" <i>J. Neuroscience</i> , December 2002, 22(23):10408-10415.		
VA	R26	KREKOSKI, C.A. <i>et al.</i> "Axonal Regeneration into Acellular Nerve Grafts Is Enhanced by Degradation of Chondroitin Sulfate Proteoglycan" <i>The Journal of Neuroscience</i> , August 15, 2001, 21(16):6206-6213.		

Examiner Signature	<i>V. Aframon</i>	Date Considered	1-27-2006
--------------------	-------------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/088 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

+

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number	10/812,776 March 29, 2004 David F. Muir 3731 UF-336XC3D1	
Sheet	5	of	7		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
VA	R27	LA FLEUR, M. <i>et al.</i> "Basement Membrane and Repair of Injury to Peripheral Nerve: Defining a Potential Role for Macrophages, Matrix Metalloproteinases, and Tissue Inhibitor of Metalloproteinases-1" <i>J. Exp. Med.</i> , December 1996, 184:2311-2326.		
VA	R28	LANGLEY, J.N. and H.K. ANDERSON "The Union of Different Kinds of Nerve Fibres" <i>J Physiol</i> , 1904, 31:365-391.		
VA	R29	LASSNER, F. <i>et al.</i> "Preservation of Peripheral Nerve Grafts: A Comparison of Normal Saline, HTK Organ Preservation Solution, and DMEM Schwann Cell Culture Medium" <i>J Reconstr Microsurg</i> , 1995, 11:447-453.		
VA	R30	LEMONS, M.L. <i>et al.</i> "Chondroitin Sulfate Proteoglycan Immunoreactivity Increases Following Spinal Cord Injury and Transplantation" <i>Exper. Neuro.</i> , 1999, 160:51-65.		
VA	R31	LEVI, A. <i>et al.</i> "Cold Storage of Peripheral Nerves: An In Vitro Assay of Cell Viability and Function" <i>Glia</i> , 1994, 10:121-131.		
VA	R32	MCKEON, R.J. <i>et al.</i> "Injury-Induced Proteoglycans Inhibit the Potential for Laminin-Mediated Axon Growth on Astrocytic Scars" <i>Exp. Neuro.</i> , 1995, 136:32-43.		
VA	R33	MCKEON, R.J. <i>et al.</i> "Reduction of Neurite Outgrowth in a Model of Glial Scarring following CNS Injury is Correlated with the Expression of Inhibitory Molecules on Reactive Astrocytes" <i>J. Neurosci.</i> , 1991, 11(11):3398-3411.		
VA	R34	MOON, L. <i>et al.</i> "Regeneration of CNS axons back to their target following treatment of adult rat brain with chondroitinase ABC" <i>Nature Neuroscience</i> , May 2001, 4(5):465-466.		
VA	R35	MUIR, D.F. "Enzymatic De-Inhibition of Axonal Regeneration", Abstract, Grant No. 1R01NS037901-01A1, Computer Retrieval of Information on Scientific Projects (CRISP) database, http://crisp.cit.nih.gov/ , maintained by the Office of Extramural Research at the National Institutes of Health (NIH), April 2, 2001.		
VA	R36	MUIR, D. <i>et al.</i> "Schwannoma Cell-derived Inhibitor of the Neurite-promoting activity of Laminin" <i>J. Cell Biol.</i> , November 1989, 109:2353-2362.		
VA	R37	NADIM, W. <i>et al.</i> "The role of Schwann cells and basal lamina tubes in the regeneration of axons through long lengths of freeze-killed nerve grafts" <i>Neuropathol Appl Neurobiol</i> , 1990, 16:411-421.		
VA	R38	OCHI, M. <i>et al.</i> "Nerve Regeneration in Predegenerated Basal Lamina Graft: The Effect of Duration of Predegeneration on Axonal Extension" <i>Exp Neurol</i> , 1994, 128:216-225.		
VA	R39	OLMARKER, K. <i>et al.</i> "Chondroitinase ABC (Pharmaceutical Grade) for Chemonucleolysis" <i>Spine</i> , 1996, 21:1952-1956.		

Examiner Signature	<i>V. Afari</i>	Date Considered	1-27-2006
--------------------	-----------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

+

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/812,776
				Filing Date	March 29, 2004
				First Named Inventor	David F. Muir
				Group Art Unit	3731
				Examiner Name	
Sheet	6	of	7	Attorney Docket Number	UF-336XC3D1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
VA	R40	SALONEN, V. <i>et al.</i> "Laminin in traumatized peripheral nerve: basement membrane changes during degeneration and regeneration" <i>J Neurocytol</i> , 1987, 16:713-720.		
VA	R41	SHUBAYEV, V.I. and R.R. MYERS "Upregulation and interaction of TNF α and gelatinases A and B in painful peripheral nerve injury" <i>Brain Res</i> , 2000, 855:83-89.		
VA	R42	SIEBERT, H. <i>et al.</i> "Matrix Metalloproteinase Expression and Inhibition After Sciatic Nerve Axotomy" <i>J Neuropathol Exp Neurol</i> , January 2001, 60(1):85-93.		
VA	R43	SMITH-THOMAS, L.C. <i>et al.</i> "Increased axon regeneration in astrocytes grown in the presence of proteoglycan synthesis inhibitors" <i>J. Cell Sci.</i> , 1995, 108:1307-1315.		
VA	R44	SMITH-THOMAS, L.C. <i>et al.</i> "An inhibitor of neurite outgrowth produced by astrocytes" <i>J. Cell Sci.</i> , 1994, 107:1687-1695.		
VA	R45	STOLL, G. and H.W. MÜLLER "Nerve Injury, Axonal Degeneration and Neural Regeneration: Basic Insights" <i>Brain Pathology</i> , 1999, 9:313-325.		
VA	R46	STRASBERG, S.R. <i>et al.</i> "Peripheral Nerve Allograft Preservation Improves Regeneration and Decreases Systemic Cyclosporin A Requirements" <i>Experimental Neurology</i> , 1996, 139:306-316.		
VA	R47	TASKINEN, H.S. and M. RÖYTTÄ "The dynamics of macrophage recruitment after nerve transection" <i>Acta Neuropathol (Berl)</i> , 1997, 93:252-259.		
VA	R48	TKALEC, A.L. <i>et al.</i> "Isolation and Expression in <i>Escherichia coli</i> of <i>csIA</i> and <i>csIB</i> , Genes Coding for the Chondroitin Sulfate-Degrading Enzymes Chondroitinase AC and Chondroitinase B, Respectively, from <i>Flavobacterium heparinum</i> " <i>Appl. Environ. Microbiol.</i> , Jan. 2000, 66(1):29-35.		
VA	R49	WANG, G-Y. <i>et al.</i> "The role of laminin, a component of Schwann cell basal lamina, in rat sciatic nerve regeneration within antiserum-treated nerve grafts" <i>Brain Res</i> , 1992, 570:116-125.		
VA	R50	YAMADA, T. <i>et al.</i> "Selective localization of gelatinase A, an enzyme degrading β -amyloid protein, in white matter microglia and in Schwann cells" <i>Acta Neuropathol (Berl)</i> , 1995, 89:199-203.		
VA	R51	YICK, L-W. <i>et al.</i> "Chondroitinase ABC promotes axonal regeneration of Clarke's neurons after spinal cord injury" <i>NeuroReport</i> , 2000, 11(5):1063-1067.		
VA	R52	ZUO, J. <i>et al.</i> "Degradation of Chondroitin Sulfate Proteoglycan Enhances the Neurite-Promoting Potential of Spinal Cord Tissue" <i>Exp Neurol</i> , 1998, 154:654-662.		

Examiner Signature	<i>V. Johnson</i>	Date Considered	1-27-2006
--------------------	-------------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

+

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/812,776
				Filing Date	March 29, 2004
				First Named Inventor	David F. Muir
				Group Art Unit	3731
				Examiner Name	
Sheet	7	of	7	Attorney Docket Number	UF-336XC3D1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
VA	R53	ZUO, J. <i>et al.</i> "Chondroitin Sulfate Proteoglycan with Neurite-Inhibiting Activity Is Up-regulated following Peripheral Nerve Injury" <i>J Neurobiol</i> , 1998, 34:41-54.		
VA	R54	ZUO, J. <i>et al.</i> "Neuronal Matrix Metalloproteinase-2 Degrades and Inactivates a Neurite-Inhibiting Chondroitin Sulfate Proteoglycan" <i>The Journal of Neuroscience</i> , July 15, 1998, 18(4):5203-5211.		
VA	R55	ZUO, J. <i>et al.</i> "Regeneration of Axons after Nerve Transection Repair Is Enhanced by Degradation of Chondroitin Sulfate Proteoglycan" <i>Exp. Neurology</i> , 2002, 176:221-228.		
VA	R56	New Zealand Examination Report dated May 20, 2004: cited in counterpart New Zealand application no. 531129.		
	R57			
	R58			
	R59			
	R60			
	R61			
	R62			
	R63			
	R64			
	R65			

Examiner Signature	V. Afremov	Date Considered	1-27-2006
--------------------	------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

+

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



SHEET 1 OF 1

FORM PTO - 1449				ATTORNEY DOCKET NO.: AXO-003C1					
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				APPLICANT: Muir					
				SERIAL NO.: 10/812,776					
				FILING DATE: March 29, 2004					
				GROUP ART UNIT: 3731					
				CONFIRMATION NO.: 4996					
U.S. PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE		
VA	A1	2003/0040112	02/27/03	Muir			8/13/02		
VA	A2	2003/0072749	04/17/03	Muir			8/13/02		
VA	A3	2003/0077258	04/24/03	Muir			8/13/02		
FOREIGN PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
VA	B1	WO2003/015612 A3	02/27/03	PCT			08/13/02	N	Y
OTHER ART, JOURNAL ARTICLES, ETC.									
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)								
VA	C1	Schmalfeldt et al., "Brain Derived Versican V2 is a Potent Inhibitor of Axonal Growth," <i>Journal of Cell Science</i> 113: 807-816 (2000).							
VA	C2	International Search Report for Patent Application Serial No. PCT/US02/25922, mailed on June 17, 2003.							
EXAMINER		V. Afrosin			DATE CONSIDERED		1-27-2006		

3100787



FORM PTO - 1449				ATTORNEY DOCKET NO.: AXO-003C1					
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				APPLICANT(S): Muir					
				SERIAL NO.: 10/812,776					
				FILING DATE: March 29, 2004					
				GROUP: 1651					
U.S. PATENT DOCUMENTS									
EXAM INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE		
VA	A4	6,448,076	9/10/2002	Dennis <i>et al.</i>			6/29/2001		
VA	A5	6,033,660	3/07/2000	Mather <i>et al.</i>			5/10/1995		
FOREIGN PATENT DOCUMENTS									
EXAM INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
OTHER ART, JOURNAL ARTICLES, ETC.									
EXAM INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)								
EXAMINER	V. Gromer				DATE CONSIDERED 1-27-2007				